Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia

Am Surg. 1991 Feb;57(2):76-9.

Abstract

Ischemia of the lower extremity has been shown to cause pulmonary leukostasis and increased pulmonary artery pressure. Thromboxane (TX) has been implicated as a mediator in this process. The effect of OKY-046, a TX synthetase inhibitor, on polymorphonuclear leukocyte (PMN) production of superoxide anion (O2-) as determined by ferricytochrome reduction was examined. Fourteen dogs were subjected to 6 hours of bilateral gracilis muscle ischemia followed by 1 hour of reperfusion. O2- production from resting PMNs and PMNs stimulated with opsonized zymosan (OZ, 0.1 mg/ml) was measured prior to ischemia or drug treatment (baseline), and following reperfusion in both treated (n = 7) and control groups (n = 7). Serum TX levels were measured using a radioimmunoassay. Following reperfusion, TX levels in the treated group were decreased as compared with the control group (18 +/- 2 pg/ml vs. 72 +/- 26 pg/ml, P less than 0.05). Superoxide production by both resting and stimulated PMNs was also decreased in the treated group; from 0.98 +/- 0.16 nmol to 0.43 +/- 0.12 nmol O2- in the resting state (P less than 0.05) and from 13.3 +/- 1.5 nmol to 9.0 +/- 1.1 nmol O2- after stimulation (P less than 0.005). O2- production was increased in the control group following reperfusion as compared with baseline samples, and this increase was attenuated by treatment with OKY-046. TX synthetase inhibition decreases activation of PMNs following hindlimb ischemia.

MeSH terms

  • Animals
  • Dogs
  • Female
  • Injections, Intravenous
  • Ischemia / complications*
  • Leg / blood supply*
  • Lung Diseases / blood
  • Lung Diseases / drug therapy*
  • Lung Diseases / etiology
  • Lymphocyte Activation / drug effects*
  • Lymphocyte Activation / physiology
  • Male
  • Methacrylates / administration & dosage
  • Methacrylates / pharmacology*
  • Methacrylates / therapeutic use
  • Neutrophils / drug effects*
  • Neutrophils / physiology
  • Superoxides / blood*
  • Thromboxane B2 / blood
  • Thromboxane-A Synthase / antagonists & inhibitors*

Substances

  • Methacrylates
  • Superoxides
  • Thromboxane B2
  • Thromboxane-A Synthase
  • ozagrel